Free Trial

Palisade Bio (PALI) Stock Price, News & Analysis

-0.12 (-2.71%)
(As of 07/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
12,060 shs
Average Volume
609,165 shs
Market Capitalization
$4.04 million
P/E Ratio
Dividend Yield
Price Target

Palisade Bio MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
423.3% Upside
$22.50 Price Target
Short Interest
2.60% of Float Sold Short
Dividend Strength
News Sentiment
0.85mentions of Palisade Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$9,670 Bought Last Quarter
Proj. Earnings Growth
From ($10.81) to ($3.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

PALI stock logo

About Palisade Bio Stock (NASDAQ:PALI)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

PALI Stock Price History

PALI Stock News Headlines

Palisade Bio (NASDAQ:PALI) Shares Up 1.1%
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
I’m giving you the name of this investment for free
I want to help you achieve that right by accessing a new business model in America that has been unlocked by a billionaire who may end up sitting in Trump’s cabinet.
Palisade Bio, Inc. (PALI)
Palisade Bio GAAP EPS of -$4.59
See More Headlines
Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$18.29 per share


Free Float
Market Cap
$4.04 million
Not Optionable
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

PALI Stock Analysis - Frequently Asked Questions

How have PALI shares performed this year?

Palisade Bio's stock was trading at $8.85 at the beginning of the year. Since then, PALI stock has decreased by 51.4% and is now trading at $4.30.
View the best growth stocks for 2024 here

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) announced its quarterly earnings results on Monday, May, 13th. The company reported ($4.59) EPS for the quarter.

When did Palisade Bio's stock split?

Palisade Bio's stock reverse split on Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Palisade Bio?

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PALI) was last updated on 7/18/2024 by Staff

From Our Partners